Author:
Arnes Jarle B.,Stefansson Ingunn M.,Straume Oddbjørn,Baak Jan P.,Lønning Per E.,Foulkes William D.,Akslen Lars A.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186
2. FDA (2004) FDA approves first angiogenesis inhibitor to treat colorectal cancer. US Food and Drug Administration. http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html . Accessed 24 Oct 2008
3. FDA (2008) New approval for Bevacizumab (Avastin). US Food and Drug Administration. http://www.fda.gov/cder/Offices/OODP/whatsnew/bevacizumab200802.htm . Accessed 24 Oct 2008
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676. doi: 10.1056/NEJMoa072113
5. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247. doi: 10.1200/JCO.2008.21.6457
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献